

Disclaimer

Summary of information: This presentation contains general and background information about Mach7 Technologies Limited ("M7T") activities current as at the date of the presentation and should not be considered to be comprehensive or to comprise all the information that an investor should consider when making an investment decision. This presentation is not a prospectus, disclosure document, product disclosure statement or other offering document under Australian law or under any other law. The presentation does not purport to contain all the information that a prospective investor may require in assessing a possible investment in M7T nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the Corporations Act 2001 (Cth). The information provided is in summary form, has not been independently verified, and should not be considered to be comprehensive or complete. It should be read solely in conjunction with the oral briefing provided by M7T and all other documents provided to you by M7T. The information in this presentation remains subject to change without notice. M7T is not responsible for providing updated information and assumes no responsibility to do so.

Not financial product advice: This financial information provided in this presentation is for information purposes only. The information contained in this presentation is of a general nature only and is not a financial product, investment advice or a recommendation to acquire M7T securities and has been prepared without taking into account the objectives, financial situation or needs of any person or entity. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. M7T is not licensed to provide financial product advice in respect of its securities or and other financial products. Cooling off rights do not apply to the acquisition of M7T securities. M7T assumes that the recipient is capable of making its own independent assessment, without reliance on this document, of the information and potential investment and will conduct its own investigation.

Disclaimer: M7T and its related bodies corporate and each of their respective directors, agents, officers, employees and advisors expressly disclaim, to the maximum extent permitted by the law, all abilities (however, caused, including negligence) in respect of, make no representations regarding, and take no responsibility for, any part of this presentation or warranty as to the currency, accuracy, reliability or completeness of any information, statements, opinions, conclusions or representations contained in this presentation. In particular, this presentation does not constitute, and shall not be relied upon as, a promise, representation, warranty or guarantee as to the past, present or future performance of M7T.

Future performance: This presentation contains certain forward-looking statements and opinions. The forward-looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward-looking statements, including projections, forecasts and estimates, are provided as a general guide only and should not be relied on as an indication or guarantee of future performance and involve known and unknown risks, uncertainties and other factors, many of which are outside the control of M7T. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast.

Risks: An investment in M7T securities is subject to investment and other known and unknown risks, some of which are beyond the control of M7T. You should have regard to the 'Key Risks' section of this presentation which outlines some of these risks.

Not an offer: This presentation is not, and should not be considered as, an offer or an invitation to acquire securities in M7T or any other financial products and neither this document nor any of its contents will form the basis of any contract or commitment. This presentation is not a prospectus. Offers of securities in M7T will only be made in places which, or to persons to whom it would be lawful to make such offers. This presentation must not be disclosed to any other party and does not carry any right of publication. Neither this presentation nor any of its contents may be reproduced or used for any other purpose without the prior written consent of M7T.

No distribution in the US: This presentation is not an offer of securities for sale in the United States. Any securities to be issued by M7T have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") and may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act. No public offer of the securities is being made in the United States and the information contained herein does not constitute an offer of securities for sale in the United States. This presentation is not for distribution directly in or into the United States or to US persons.

Monetary values: Unless otherwise stated, all dollar values are in Australian dollars (AUD\$). The information in this presentation remains subject to change without notice.

Sophisticated and professional investor: By attending this presentation, you present and warrant that (i) if you are in Australia, you are a person to whom an offer of securities may be made without a disclosure document as defined in the Corporation Act 2001 (Cth) ("Corporation Act")) on the basis that you are exempt from the disclosure requirements of Part 6D.2 in accordance with Section 708(8) or 708(11) of the Corporations Act; (ii) if you are in the United States, you are a qualified institutional buyer (as defined under Rule 144A Under the U.S. Securities Act; (iii) if you are outside Australia and the United States, you are a person to whom an offer and issue of securities can be made outside Australia without registration, lodgement or approval of a formal disclosure document or other filing in accordance with the laws of that foreign jurisdiction. If you are not such a person, you are not entitled to attend this presentation. Please return this presentation and any copies and do not provide this presentation to any other person.

No distribution: Distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable security laws.




MACH7 BUSINESS HIGHLIGHTS – FY18



Sales growth

- Pipeline +50% (last 15 months)
- Growing global customer base across healthcare tiers



Expanding the addressable market to ~\$4b

- Engagement of distributors and value-added resellers
- Entry into new markets: LATAM & Europe



Product innovation

- Expanded solution offering via partnerships – enterprise & diagnostic viewer, care coordination, Artificial Intelligence, document management solutions and more
- Version 11.8 PACS replacement




Enhanced leadership


Restructured Board of Directors, adding world-renowned radiologist and A.I. enthusiast, and experienced CEO from PACS and EMR industry



FINANCIAL HIGHLIGHTS – FY18







Cash on Hand +\$2.5m with no debt

More than FY18 operational outflows of \$2.2m

MACH7 GROWTH PATH













2007
Mach7 Founded

2010

First Pilots Deployed Cloud Deployments USA & Middle East 2012

First Commercial Wins Revenue Phase Begins 2016

Listed on ASX (M7T)

2018 | 2019

New Diagnostic, Connected Health and Al Solutions



Growing our addressable market through portfolio and market expansion

Enterprise Imaging (VNA) market ~ \$600M

Enterprise Imaging & PACS
Replacement market ~\$3.9B - 2024
Al Medical Imaging ~\$2.5B - 2024
Connected Healthcare ~\$150B - 2024

Today's Healthcare Problem

Inefficient health care delivery due to ~70% of clinical data living outside of the EMR

The Mach7 Solution

A **proven, unique and innovative platform** that enables access, interoperability, and liquidity of patient data.

Delivering Outcomes

Improved patient care through the delivery of clinical, business and operational improvements, resulting in lower costs & increased efficiencies.

Enabling Care Teams to Connect & Collaborate

Enabling Telehealth -Delivery

Aggregate Clinical Data Reduce Redundant Technology Lower Procedure Costs

Cheaper to Deploy



MACH7 SOLUTIONS

Enterprise Solutions (current revenue)

Diagnostic Solutions (new revenue)


Connected Healthcare (new revenue)

Artificial Intelligence (new revenue)









- VNA
- Enterprise Viewing
- Image Distribution

- PACS
- Worklist
- QC

- Image Sharing
- Care Coordination
- Physician Portal
- Interoperability
- Telehealth

- Analytics
- Assisted Diagnosis



MACH7 PLATFORM (CORE I.P.)

UNIQUE COMPETITIVE ADVANTAGES

Innovative platform with intuitive, pointand-click interface and real-time monitoring dashboard


Proprietary technology that intelligently brings together multiple image formats into a cohesive workflow

Scalable software that grows with the customer

Artificial Intelligence enabled for operational analytics & clinical applications

Highly recommended by customers and industry

Worldwide presence with regional support



STRATEGY FOR SUCCESS

New regions through indirect channels, VAR, and OEM partners

Innovate & disrupt the market Innovative healthcare data services, intelligent platform & reconstructed PACS

Enter new markets



Solve common problems Innovative workflow improvement services

Customer

- Grow the app ecosystem
- New application verticals on the platform
- Technology partners

Grow through partnerships




Improved outcomes

Focus on customer outcomes, clinical improvements, revenue growth and internal cost efficiency



GROWING GLOBAL CUSTOMER BASE



MACH7

MACH7 BOARD AND MANAGEMENT



Damien Lim NON-EXECUTIVE CHAIRMAN

- 21+ years experience in private equity and investment banking
- Co-founder of BioVeda Capital
- Currently serves on a number of boards and advisory committees



Eliot Siegel, MD NON-EXECUTIVE DIRECTOR

- Thought leader in the world of radiology and imaging informatics. Professor and Vice Chair at the University of Maryland School of Medicine
- Chief of Radiology & Nuc Med for the Veterans Affairs Maryland Healthcare System.



Mike Jackman MANAGING DIRECTOR, CEO

- Experienced HCIT executive
- Formerly Americas Region CEO HCIT at GE Healthcare
- The business leader responsible for the GE Healthcare Digital business in Latin America, US, and Canada



Jenni Pilcher CFO, Company Secretary



- Former CFO of Alchemia, and CFO and Co-Sec of Mesoblast (ASX:MSB)
- Part of global finance teams at Cadbury Schweppes and Medeva plc



Eric Rice

- 20 years of systems architecture and design, engineering and management experience
- Held leadership roles and designed solutions for GE Healthcare



David
Chambers
NON-EXECUTIVE
DIRECTOR

- 30+ years' extensive experience in HCIT and Life Science industry.
- Former CEO of Promedicus & Visage Imaging
- Currently Managing Director, Asia-Pacific, of Allscripts Healthcare Solutions,



Wayne Spittle NON-EXECUTIVE DIRECTOR

- Extensive industry experience in the global healthcare
- Currently: consultant at Samsung Medison; Advisor at Novum Waves
- Former Executive VP with Samsung Medison and Health and Medical Equipment division



Ravi Krishnan FOUNDER, CSO

- Founding partner of Mach7 Technologies
- Nearly 20 years of experience with technology intricacies that drive medical imaging
- Previously worked at GE
 Healthcare and Agfa
 Healthcare



Mike Lampron

- 20+ years experience in business and operational management for HCIT companies
- Mike is responsible for our customers' success while driving excellence

MACH7 TECHNOLOGIES (M7T:AX)

CAPITAL STRUCTURE

Share price (3-Sep-18)	\$0.21
Number of shares (m) ¹	132.2m
Market Capitalisation	\$27.8m
Cash (30-June 18)	\$2.5m
Debt (30-June 18)	nil
Enterprise Value	\$25.0m

1. Excludes 13.9m unlisted performance rights/options

MAJOR SHAREHOLDERS

	# shares (m)	%
JM Financial Group (Melbourne, Australia)	15.7	11.9%
Oceania Capital Partners (Sydney, Australia)	12.4	9.4%
BV Healthcare II (BioVeda Capital, Singapore)	11.4	8.6%
Ravindran Krishnan (Mach7 Founder, Singapore)	5.5	4.4%
Directors, Staff (excl. Ravi K)	~6.6	5.0%

Note: ~70% of shares held by Top 20.

~1400 shareholders

FULL YEAR 2018 RESULT

P&L	FY 2018 A\$m	FY 2017 A\$m	% Change
Revenue	8.6	\$10.3	-16%
Operating expenditure	(11.6)	(\$14.6)	-21%
Other income/expenses	0.3	0.1	225%
EBITDA (adjusted)	(2.6)	(4.2)	-38%
Share-based payments	(1.0)	(0.5)	113%
Interest expense	(0.0)	(0.2)	-95%
Impairment charges	0.0	(11.7)	-100%
Dep'n / Amort'n	(1.3)	(1.1)	-25%
Loss for the year	(4.9)	(17.7)	-72%

- ✓ EBITDA improvement +38%
- ✓ Loss improvement +72%

BALANCE SHEET	FY 2018 A\$m	FY 2017 A\$m	% Change
Cash	2.5	2.7	-7%
Net tangible assets	3.0	3.4	-13%
Deferred revenue	2.7	2.9	-5%
Debt	0.0	0.0	-100%

CASH FLOWS	FY 2018 A\$m	FY 2017 A\$m	% Change
Cash outflows from operations	(2.2)	(5.2)	-58%

- ✓ Net tangible assets + Deferred revenue = \$5.7M
- ✓ Cash outflows from operations improvement +58%
- ✓ Cash on hand covers last annual operational outflows